Pharmacology of a new antidepressant: Benefit of the implication of the melatonergic system

International Clinical Psychopharmacology

Volumn 21, Issue SUPPL. 1, 2006, Pages

  Fuchs, Eberhard ^a,b   Simon, Maria ^a   Schmelting, Barthel ^a  

^a GERMAN PRIMATE CENTER   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

5 HT2c receptors; Animal models; Circadian rhythm; Depression; HPA axis; Melatonin receptors; Tree shrews

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; MONOAMINE OXIDASE INHIBITOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BINDING AFFINITY; BIOLOGICAL RHYTHM; CHRONOBIOLOGY; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL CLOCKS; BRAIN; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; MELATONIN; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C; TUPAIIDAE;

EID: 33646672157     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000199456.39552.c7     Document Type: Article

References (30)

1. Armstrong SM, McNulty OM, Guardiola-Lemaître B, Redman JR (1993). Successful use of S 20098 and melatonin in an animal model of delayed sleep-phase syndrome. Pharmacol Biochem Behav 46:45-49.
2. Bahr NI, Palme R, Möhle U, Hodges JK, Heistermann M (2000). Comparative aspects of the metabolism and excretion of cortisol in three individual nonhuman primates. Gen Comp Endocrinol 117:427-438.
3. Bourin M, Mocaer E, Porsolt R (2004). Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 29:126-133.
4. Bosker FJ, Westerink BH, Cremers TI, Gerrits M, van der Hart MG, Kuipers SD (2004). Future antidepressants: what is in the pipeline and what is missing? CNS Drugs 18:705-732.
5. Cardinali DP, Brusco LI, Furio AM (2002). Melatonin in sleep disorders: pathophysiology and potential approaches to management. Neuro Endocrinol Lett 23 (suppl 1):9-13.
6. Crasson M, Kjiri S, Colin A, Kriri K, L'Hermite-Baleriaux M, Ansseau M, Legros JJ (2004). Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 29:1-12.
7. Cussac D, Newman-Tancredi A, Pasteau V, Millan MJ (2002). Antagonist properties of the melatonin agonist S 20098 (agomelatine) at recombinant, human (h) serotonin (5-HT2c) receptors. Int J Neuropsychopharmacol 5:68.
8. DSM-IV (1994). Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association.
9. Fuchs E (2005). Social stress in tree shrews as an animal model of depression: an example of a behavioral model of a CNS disorder. CNS Spectr 10:182-190.
10. Fuchs E, Flugge G (2002). Social stress in tree shrews: effects on physiology, brain function and behavior of subordinate individuals. Pharmacol Biochem Behav 73:247-258.
11. Fuchs E, Schumacher M (1990). Psychosocial stress affects pineal function in the tree shrew (Tupaia belangeri). Physiol Behav 47:713-717.
12. Fuchs E, Kramer M, Hermes B, Netter P, Hiemke C (1996). Psychosocial stress in tree shrews: clomipramine counteracts behavioral and endocrine changes. Pharmacol Biochem Behav 54:219-228.
13. Hanoun N, Mocaer E, Boyer PA, Hamon M, Lanfumey L (2004). Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 47:515-526.
14. Holsboer F, Barden N (1996). Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 17:187-205.
15. Jindal RD, Thase ME (2004). Treatment of insomnia associated with clinical depression. Sleep Med Rev 8:19-30.
16. Judd LL, Paulus MP, Wells KB, Rapaport MH (1996). Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 153:1411-1417.
17. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ et al. (1998). 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924.
18. Martinet L, Guardiola-Lemaître B, Mocaër E (1996). Entrainment of circadian rhythms by S 20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 54:713-718.
19. 2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954-964.
20. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349:1498-1504.
21. Papp M, Gruca P, Boyer PA, Mocaër E (2003). Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694-703.
22. Reiter RJ, Tan DX, Qi W, Manchester LC, Karbownik M, Calvo JR (2000). Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 9:160-171.
23. Reul JM, Stec I, Soder M, Holsboer F (1993). Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133:312-320.
24. Riedel WJ, Klaassen T, Griez E, Honig A, Menheere PPCA, Van Praag HM (2002). Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood. Neuropsychopharmacology 26:358-367.
25. Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukush DK, Gallagher TF (1973). Disrupted 24 hour patterns of cortisol secretion in psychotic depressives. Arch Gen Psychiatry 28:19-24.
26. Sanchez C, Hyttel J (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467-489.
27. Schildkraut JJ (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509-522.
28. Wehr TA, Wirz-Justice A (1982). Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatry 15:31-39.
29. Ying SW, Rusak B, Delagrange P, Mocaër E, Renard P, Guardiola-Lemaître B (1996). Melatonin analogues as agonist and antagonists in the circadian system and other brain areas. Eur J Pharmacol 396:33-42.
30. Zisapel N (2001). Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 15:311-328.